In Reply Dr Pollack is concerned about the lack of evidence for deferasirox therapy in people with SCD and iron overload, as well as potential adverse effects and high costs. He refers to recent advances in the understanding of hepatic pathophysiology in handling iron and comments that this may apply to people with thalassemia, correctly pointing out that it is not clear if those data also apply to patients with SCD.1
Yawn BP, Buchanan G, Hassell K. Management of Patients With Sickle Cell Disease—Reply. JAMA. 2015;313(1):91–92. doi:10.1001/jama.2014.15909
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: